

The African Esophageal Cancer Consortium: A Call to Action

Katherine Van Loon
 Michael M. Mwachiro
 Christian C. Abnet
 Larry Akoko
 Mathewos Assefa
 Stephen L. Burgert
 Steady Chasimpha
 Charles Dzamalala
 David E. Fleischer
 Satish Gopal
 Prasad G. Iyer
 Bongani Kaimila
 Violet Kayamba
 Paul Kelly
 Maria E. Leon
 Christopher G. Mathew
 Diana Menya
 Daniel Middleton
 Yohannie Mlombe
 Blandina T. Mmbaga
 Elia Mmbaga
 Gift Mulima
 Gwen Murphy
 Beatrice Mushi
 Ally Mwanga
 Amos Mwasamwaja
 M. Iqbal Parker
 Natalie Pritchett
 Joachim Schüz
 Mark D. Topazian
 Russell E. White
 Valerie McCormack
 Sanford M. Dawsey

Author affiliations and support information (if applicable) appear at the end of this article.
 (continued)

Executive summary

Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of cancer-related death; however, worldwide incidence and mortality rates do not reflect the geographic variations in the occurrence of this disease. In recent years, increased attention has been focused on the high incidence of esophageal squamous cell carcinoma (ESCC) throughout the eastern corridor of Africa, extending from Ethiopia to South Africa. Nascent investigations are underway at a number of sites throughout the region in an effort to improve our understanding of the etiology behind the high incidence of ESCC in this region. In 2017, these sites established the African Esophageal Cancer Consortium. Here, we summarize the priorities of this newly established consortium: to implement coordinated multisite investigations into etiology and identify targets for primary prevention; to address the impact of the clinical burden of ESCC via capacity building and shared resources in treatment and palliative care; and to heighten awareness of ESCC among physicians, at-risk populations, policy makers, and funding agencies.

Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of cancer-related death; however, worldwide incidence and mortality rates do not reflect the geographic variations in the occurrence of this disease.¹ More than 80% of cases and deaths from esophageal cancer occur in developing countries, and geographically defined high-incidence regions are a striking and distinguishing characteristic of this malignancy. In contrast to the economically developed world, where the dominant subtype of esophageal cancer is adenocarcinoma, esophageal squamous cell carcinoma (ESCC) is the dominant subtype in high-incidence areas, including Africa.

High-incidence areas for ESCC have been known and studied for years in northern China, north-eastern Iran, southern South America, and South Africa.²⁻⁹ Another geographically defined high-incidence area is the eastern corridor of Africa. The common occurrence of ESCC along this corridor was documented more than a half-century ago and mapped as far back as 1969.¹⁰ More recent evidence has demonstrated that this region—extending from Ethiopia to South Africa—remains disproportionately impacted by the high incidence of ESCC.^{11,12} In stark contrast, esophageal cancer is much less common in Western or Northern Africa¹ (Fig 1).

Reflecting the significant impact of ESCC in the developing world, the US National Cancer Institute (NCI) and the International Agency for

Research on Cancer (IARC) convened an International Tumor Workshop on Esophageal Squamous Cell Carcinoma in September 2016.¹⁴ Whereas this meeting was attended by international experts who represented multiple high-incidence regions throughout the developing world, a substantial focus was on the emerging data and unmet needs related to the high incidence of ESCC in sub-Saharan Africa. At this meeting, a critical mass of African investigators and their international partners initiated the African Esophageal Cancer Consortium (AfrECC) to facilitate research collaborations in environmental, molecular, and genetic epidemiology; early detection, clinical management, treatment, and palliation; capacity building; and interventions to reduce the burden of ESCC in sub-Saharan Africa.

CURRENT AfrECC SITES

During the past few years, several groups have initiated epidemiologic and molecular studies of ESCC at sites in sub-Saharan Africa, including Dar es Salaam, Tanzania (Muhimbili University of Health and Allied Sciences, Ocean Road Cancer Institute, and University of California, San Francisco); Eldoret, Kenya (Moi University and IARC); Bomet, Kenya (Tenwek Hospital and NCI); Moshi, Tanzania (Kilimanjaro Clinical Research Institute and IARC); Lilongwe, Malawi (The University of North Carolina Project-Malawi and NCI); Blantyre, Malawi (Queen Elizabeth

Corresponding author:
Katherine Van Loon, MD,
Global Cancer Program,
Helen Diller Family
Comprehensive Cancer
Center, University of
California, San Francisco,
550 16th St, 6th Floor,
San Francisco, CA
94143; e-mail: katherine.
vanloon@ucsf.edu.

Central Hospital and IARC); Lusaka, Zambia (Tropical Gastroenterology and Nutrition Group, University of Zambia); Addis Ababa, Ethiopia (Addis Ababa University and IARC); and Johannesburg and Cape Town, South Africa (University of the Witwatersrand and University of Cape Town). These groups have now joined together in AfrECC (Fig 2) to share expertise, infrastructure, and resources and to ensure that all present and future participant sites in sub-Saharan Africa fully benefit from our collaborative work. During regular conference calls, participants review ongoing activities, identify opportunities and challenges, and plan for the coordination of multisite efforts. In May 2017, AfrECC members convened in East Africa and conducted visits to several AfrECC sites to learn from each other and facilitate closer collaboration. In the future, we aim to establish formal membership guidelines and pursue shared research funding to optimize the impact of our resources and efforts to reduce mortality and suffering from ESCC in this region.

CURRENT AfrECC PRIORITIES

Implement Coordinated Multisite Investigations Into the Etiology of ESCC in East Africa and Identify Targets for Primary Prevention

Studies from China and Iran, as well as from the United States, Europe, and Japan, demonstrate considerable etiologic heterogeneity for ESCC, with evidence that major risk factors in one population may play a more limited role in other populations. Whereas etiologic and genetic studies of esophageal cancer in Asian populations have been relatively extensive, the high-incidence region along the eastern corridor of Africa remains largely unstudied. We recently conducted an extensive review to assess whether ESCC risk factors that have been established or are likely in other parts of the world are also present in the African context. Whereas many were identified, most have not been carefully studied in Africa.¹⁵ Moreover, in a number of East African populations, we observed a disproportionate number (approximately 20%) of patients who were diagnosed at younger than 40 years old.^{12,16-19} This high incidence of ESCC in patients younger

Fig 1. National-level map of age-standardized incidence rate (ASR) of esophageal squamous cell carcinoma in women and men (Arnold et al¹³).






Fig 2. Current participant sites in the African Esophageal Cancer Consortium (AfrECC).

than 40 years, as well as the geographic variation associated with this diagnosis, suggests plausible roles for unique environmental, infectious, and/or genetic risk factors in this region. Identification of environmental, molecular, and genetic factors, as well as possible interactions, that contribute to the high incidence of this disease along the eastern corridor of Africa will be necessary to inform prevention and early detection strategies in this region.

Case control studies will be a primary method of etiologic research in this setting. A full case control study has completed accrual in Dar es

Salaam, Tanzania,¹⁷ and smaller studies from Zambia²⁰ and Ethiopia²¹ have been published. NCI and IARC are supporting several parallel ongoing case control studies at other AfrECC participant sites, collectively known as the ESC-CAPE case control studies.²² At the three sites that began studies in 2016 and 2017, questionnaires have been harmonized and data are being collected electronically using a mobile health application, which helps standardize the data across sites, allows centralized and remote coordination, and improves real-time quality control. Whereas each individual site has the

potential to accrue hundreds of patients, no single site is likely to identify the etiologic factors for the development of ESCC throughout the region, and no single study has the potential to confirm associations; thus, multisite collaborations with harmonized study instruments and protocols are needed to allow for comparison and validation of findings. Ultimately, we aim to merge data from multiple study sites to compare and contrast the etiological effects of lifestyle and environmental factors on ESCC across this region. Extensive questionnaire data and saliva and/or blood specimens for future DNA analyses are being collected from all study participants, and multisite genome-wide association studies, such as those previously conducted to investigate this disease in China,²³ are planned.

Case control studies will seek to identify exposures that are implicated in ESCC in Africa; however, many associations will necessarily rely on self-reported data, as biomarker-based assessments are typically not feasible as a result of the severe alteration of the exposure—for example, diet—caused by the disease. Thus, the consortium is also undertaking detailed ecologic and cross-sectional descriptive studies of specific exposures, such as hot beverages²⁴ and micronutrient deficiencies,²⁵ to understand major exposure sources, levels, and exposed population groups.

In addition, establishment of ESCC tumor biorepositories for additional genomic profiling is underway. Mutation of the tumor suppressor gene, *TP53*, has been previously reported as the most frequent genetic alteration in ESCC in other settings,^{26,27} with mutation profiles that are known to vary across geographic areas^{28,29}; however, a recent whole-exome sequencing and RNA sequencing analysis of 59 ESCC tumors

from Malawi reported a high proportion of tumors without *TP53* mutations, as well as a tumor mutation signature³⁰ that is possibly consistent with an unknown carcinogenic exposure.³¹ This sequencing study from Malawi and case series from South Africa, Zambia, and Kenya have not supported an etiologic role for human papillomavirus,^{20,32-34} and, with rare exception,^{20,35} there is no evidence of an association of ESCC with HIV, either in time trends or in case control data³⁶; however, a search for other possible infectious etiologies remains an area of active investigation.

Finally, we recognize that the sustainability and success of our research is ultimately dependent on the efforts of clinical and research colleagues in Africa, and we are committed to the provision of training in research methodology and longitudinal mentoring to enhance and promote cancer research capabilities in the region.

Address the Impact of the Clinical Burden of Esophageal Cancer Through Capacity Building and Shared Resources in Treatment and Palliative Care

As in other low- and middle-income countries, patients with ESCC in eastern Africa present with advanced disease with symptoms of dysphagia and obstruction and resultant malnutrition. Patients with ESCC are readily identifiable in surgical and medical hospital wards, profoundly wasted and holding spittoon cups to manage the secretion of saliva. The suffering of these patients is profound and weighs heavily on the minds of the physicians and nurses who care for them, many of whom share sentiments of helplessness and hopelessness because of the lack of available options for early detection, treatment or palliation.




Fig 3. Priority activities of the African Esophageal Cancer Consortium. GWAS, genome-wide association study; SEMS, self-expanding metal stent.

Meanwhile, at Tenwek Hospital, a community-based referral hospital in Bomet, Kenya, where ESCC accounts for 35% of all tumors, surgeons have deployed more than 2,000 self-expanding metal stents (SEMSs) for patients who present with esophageal obstruction. In a review of 1,000 patients who received SEMSs, this technology was demonstrated to be safe and feasible for the palliation of dysphagia symptoms related to ESCC in resource-limited settings³⁷; however, at most other sites in eastern Africa, the retail price for imported SEMSs is prohibitive for patients, a barrier that is compounded by the low socioeconomic status and insufficient health insurance of these patients. As a result of financial barriers, the poor distribution of relatively inexpensive SEMSs, and inadequate endoscopy resources and training, palliative stenting is not widely available in eastern Africa. AfrECC is pursuing several options to support advocacy for equal and fair pricing and access to SEMS for the region, as well as capacity-building activities to support endoscopic training, including SEMS placement.

A recent report from China also suggests that steady, incremental progress may eventually yield high-impact programs for ESCC screening and earlier detection, which can significantly reduce mortality.³⁸ With increased advocacy and awareness about the high incidence of ESCC impacting the region, we anticipate that earlier detection may yield an eventual trend toward increased numbers of patients presenting with tumors that are amenable to curative therapies, including endoscopic therapy, chemoradiation, and/or surgery. We aim to support the development of standardized treatment protocols that are relevant to the available resources within the region. The formation of surgical training partnerships will also facilitate training and the establishment of proficiencies in complex esophagectomy procedures. Finally, implementation strategies are needed to enhance and measure the acceptability, feasibility, and sustainability of each of these interventions, and long-term monitoring is needed to evaluate their effects on clinical outcomes.

Heighten Awareness of ESCC Among physicians, At-Risk Populations, Policy Makers, and Funding Agencies

In the absence of the capacity to provide treatment or palliation for patients with ESCC at most sites throughout eastern Africa, individuals who develop symptoms of dysphagia are commonly

reticent to seek care, and there is a pervasive perception that going to the hospital with symptoms of dysphagia means certain death. Sadly, this perception is currently not far from reality, with patients routinely presenting with extremely advanced disease and at risk for rapid deterioration; however, extrapolating from other diseases, increased awareness and education among at-risk populations and physicians may result in earlier presentations for clinical care, earlier diagnosis, and referrals to centers that are equipped to provide the necessary treatment or palliation. In addition, increased advocacy and awareness among local ministries of health and international funding agencies is critical for the provision of resources to increase access to relevant therapies and to support the necessary research to drive the development of evidence-based policies for prevention and palliation. The priority activities of the consortium are summarized in Figure 3.

CONCLUSION

In May 2017, the World Health Assembly endorsed a set of measures to improve and scale up access to prevention, early diagnosis, prompt and accessible treatment, and palliative care for cancer.³⁹ Member States called on WHO to promote access for all people to affordable cancer diagnosis and treatment and to provide countries with technical guidance to identify and implement priority cancer control interventions. WHO member states committed to ensuring adequate resources to support the implementation of national cancer control plans and to strengthen health systems to provide early diagnosis and treatment services for all patients with cancer. ESCC is one of the most prevalent and deadly cancers that afflicts eastern and southern Africa, and it is certainly one that puts vulnerable populations at risk for great morbidity and catastrophic health expenditures.

The task of scaling up care for ESCC within African health systems that are already fraught with challenges has been dismissed by some as impractical and unattainable because of the deadly nature of this disease. Whereas we acknowledge the challenges, our shared view is that this is the very attribute that makes this work urgent and imperative. We know from the evolution of the HIV epidemic that etiologic understanding, palliation, health system strengthening,

capacity building, and the gradual implementation of effective prevention, early detection, and treatment interventions can provide a path forward, even when faced with the most daunting of diseases.

Although international attention to the tremendous burden of this disease is nascent, there is burgeoning high-quality work in progress at multiple sites in Kenya, Tanzania, Malawi, Zambia, Ethiopia, and South Africa, with the development of etiologic studies, biospecimen repositories,

genome-wide association studies, and clinical training partnerships. Looking forward, we aim to enhance the ongoing efforts through increased collaboration across sites and strengthened international partnerships. Our call to action aims to raise awareness of the tremendous impact of this deadly disease on an already fragile region and to mobilize others to become involved.

DOI: <https://doi.org/10.1200/JGO.17.00163>

Published online on jgo.org on January 25, 2018.

AUTHOR CONTRIBUTIONS

Conception and design: Katherine Van Loon, Michael M. Mwachiro, Christian C. Abnet, Larry Akoko, Steady Chasimpha, Satish Gopal, Bongani Kaimila, Paul Kelly, Maria E. Leon, Christopher G. Mathew, Diana Menya, Yohannie Mlombe, Blandina T. Mmbaga, Elia Mmbaga, Gift Mulima, Beatrice Mushi, Ally Mwanga, Amos Mwasamwaja, M. Iqbal Parker, Joachim Schüz, Russell E. White, Valerie McCormack, Sanford M. Dawsey

Financial support: Christian C. Abnet

Collection and assembly of data: Michael M. Mwachiro, Larry Akoko, Mathewos Assefa, Stephen L. Burgert, Charles Dzamalala, Christopher G. Mathew, Blandina T. Mmbaga, Ally Mwanga, Amos Mwasamwaja, Russell E. White

Data analysis and interpretation: Michael M. Mwachiro, David E. Fleischer, Prasad G. Iyer, Violet Kayamba, Daniel Middleton, Gift Mulima, Gwen Murphy, Ally Mwanga, Amos Mwasamwaja, Natalie Pritchett, Mark D. Topazian, Russell E. White

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Katherine Van Loon

Consulting or Advisory Role: Bayer (Inst)

Michael M. Mwachiro

No relationship to disclose

Christian C. Abnet

No relationship to disclose

Larry Akoko

No relationship to disclose

Mathewos Assefa

No relationship to disclose

Stephen L. Burgert

No relationship to disclose

Steady Chasimpha

No relationship to disclose

Charles Dzamalala

No relationship to disclose

David E. Fleischer

No relationship to disclose

Satish Gopal

No relationship to disclose

Prasad G. Iyer

Research Funding: Intromedic, Exact Sciences, C2 Therapeutics

Consulting or Advisory Role: Medtronic, Symple Surgical

Patents, Royalties, Other Intellectual Property: Capnostics (Inst)

Travel, Accommodations, Expenses: Olympus Keymed

Bongani Kaimila

No relationship to disclose

Violet Kayamba

No relationship to disclose

Paul Kelly

Consulting or Advisory Role: Calibr (Inst)

Maria E. Leon

No relationship to disclose

Christopher G. Mathew

No relationship to disclose

Diana Menya

No relationship to disclose

Daniel Middleton

No relationship to disclose

Yohannie Mlombe

No relationship to disclose

Blandina T. Mmbaga

No relationship to disclose

Elia Mmbaga

No relationship to disclose

Gift Mulima

No relationship to disclose

Gwen Murphy

No relationship to disclose

Beatrice Mushi

No relationship to disclose

Ally Mwanga

No relationship to disclose

Amos Mwasamwaja

No relationship to disclose

M. Iqbal Parker

No relationship to disclose

Natalie Pritchett

No relationship to disclose

Joachim Schüz

Employment: Merck KGaA (I)

Mark D. Topazian

Stock and Other Ownership Interests: Metamodix

Research Funding: Celgene

Russell E. White

No relationship to disclose

Valerie McCormack

No relationship to disclose

Sanford M. Dawsey

No relationship to disclose

ACKNOWLEDGMENT

We acknowledge the Center for Global Health (CGH) of the National Cancer Institute for its encouragement and its designation of esophageal cancer as a priority disease in sub-Saharan Africa. We thank Matthew Brown of CGH and the Clinton Health Access Initiative for their ongoing partnership in developing a sustainable source for distribution and pricing regulation of self-expanding metal stents in sub-Saharan Africa.

Affiliations

Katherine Van Loon, University of California, San Francisco, San Francisco, CA; **Michael M. Mwachiro**, **Stephen L. Burgert**, and **Russell E. White**, Tenwek Hospital, Bomet; **Diana Menya**, Moi University, Eldoret, Kenya; **Christian C. Abnet**, **Gwen Murphy**, **Natalie Pritchett**, and **Sanford M. Dawsey**, National Cancer Institute, Bethesda, MD; **Larry Akoko**, **Elia Mmbaga**, **Beatrice Mushi**, and **Ally Mwanga**, Muhimbili University of Health and Allied Sciences, Dar es Salaam; **Blandina T. Mmbaga** and **Amos Mwasamwaja**, Kilimanjaro Clinical Research Institute, Moshi, Tanzania; **Mathewos Assefa**, Addis Ababa University, Addis Ababa, Ethiopia; **Steady Chasimpha** and **Charles Dzamalala**, Queen Elizabeth Central Hospital; **Charles Dzamalala**, **Satish Gopal**, **Bongani Kaimila**, and **Yohannie Mlombe**, University of Malawi College of Medicine, Blantyre; **Gift Mulima**, Kamuzu Central Hospital, Lilongwe, Malawi; **David E. Fleischer**, Mayo Clinic, Phoenix, AZ; **Satish Gopal**, University of North Carolina, Chapel Hill, NC; **Prasad G. Iyer** and **Mark D. Topazian**, Mayo Clinic, Rochester, MN; **Violet Kayamba** and **Paul Kelly**, University of Zambia, Lusaka, Zambia; **Paul Kelly**, Queen Mary University of London; **Christopher G. Mathew**, King's College London, London, United Kingdom; **Maria E. Leon**, **Daniel Middleton**, **Joachim Schüz**, and **Valerie McCormack**, International Agency for Research on Cancer, Lyon, France; **Christopher G. Mathew**, University of the Witwatersrand, Johannesburg; and **M. Iqbal Parker**, University of Cape Town, Cape Town, South Africa.

Support

The African Esophageal Cancer Consortium is supported jointly by the International Agency for Research on Cancer and the Division of Cancer Epidemiology and Genetics of the Intramural Research Program of the National Cancer Institute.

REFERENCES

1. International Agency for Research on Cancer: GLOBOCAN 2012: Cancer incidence and mortality worldwide in 2012 v1.0: IARC CancerBase No. 11. <http://publications.iarc.fr/Databases/IARC-Cancerbases/Globocan-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1-0-2012>
2. Castellsagué X, Muñoz N, De Stefani E, et al: Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. *Int J Cancer* 82:657-664, 1999
3. Kmet J, Mahboubi E: Esophageal cancer in the Caspian littoral of Iran: Initial studies. *Science* 175:846-853, 1972
4. Islami F, Kamangar F, Nasrollahzadeh D, et al: Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran: A review. *Eur J Cancer* 45:3156-3165, 2009
5. Rose EF: Esophageal cancer in the Transkei: 1955-69. *J Natl Cancer Inst* 51:7-16, 1973
6. Sewram V, Sitas F, O'Connell D, et al: Tobacco and alcohol as risk factors for oesophageal cancer in a high incidence area in South Africa. *Cancer Epidemiol* 41:113-121, 2016
7. Sumeruk R, Segal I, Te Winkel W, et al: Oesophageal cancer in three regions of South Africa. *S Afr Med J* 81:91-93, 1992

8. Tran GD, Sun XD, Abnet CC, et al: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. *Int J Cancer* 113:456-463, 2005
9. Yang CS: Research on esophageal cancer in China: A review. *Cancer Res* 40:2633-2644, 1980
10. McGlashan ND: Oesophageal cancer and alcoholic spirits in central Africa. *Gut* 10:643-650, 1969
11. Patel K, Wakhisi J, Mining S, et al: Esophageal cancer, the topmost cancer at MTRH in the Rift Valley, Kenya, and its potential risk factors. *ISRN Oncol* 2013:503249, 2013
12. Cheng ML, Zhang L, Borok M, et al: The incidence of oesophageal cancer in Eastern Africa: Identification of a new geographic hot spot? *Cancer Epidemiol* 39:143-149, 2015
13. Arnold M, Soerjomataram I, Ferlay J, et al: Global incidence of oesophageal cancer by histological subtype in 2012. *Gut* 64:381-387, 2015
14. Murphy G, McCormack V, Abedi B, et al: International cancer seminars: A focus on esophageal squamous cell carcinoma. *Ann Oncol* 28:2086-2093, 2017
15. McCormack VA, Menya D, Munishi MO, et al: Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting-specific exposures to known and putative risk factors. *Int J Cancer* 140:259-271, 2017
16. Parker RK, Dawsey SM, Abnet CC, et al: Frequent occurrence of esophageal cancer in young people in western Kenya. *Dis Esophagus* 23:128-135, 2010
17. Mmbaga E, Deardorff K, Mushi B, et al: A case-control study to evaluate the etiology of esophageal cancer in Tanzania. *J Global Oncol* 2:5s, 2016 (3_suppl)
18. Mmbaga EJ, Deardorff KV, Mushi B, et al: Characteristics of esophageal cancer cases in Tanzania. *J Global Oncol* [epub ahead of print on April 27, 2017]
19. Dawsey SP, Tonui S, Parker RK, et al: Esophageal cancer in young people: A case series of 109 cases and review of the literature. *PLoS One* 5:e14080, 2010
20. Kayamba V, Bateman AC, Asombang AW, et al: HIV infection and domestic smoke exposure, but not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: A case-control study. *Cancer Med* 4:588-595, 2015
21. Leon ME, Assefa M, Kassa E, et al: Qat use and esophageal cancer in Ethiopia: A pilot case-control study. *PLoS One* 12:e0178911, 2017
22. International Agency for Research on Cancer: Oesophageal squamous cell carcinoma African prevention research. <http://http://esccape.iarc.fr/>
23. Wu C, Wang Z, Song X, et al: Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. *Nat Genet* 46:1001-1006, 2014
24. Munishi MO, Hanisch R, Mapunda O, et al: Africa's oesophageal cancer corridor: Do hot beverages contribute? *Cancer Causes Control* 26:1477-1486, 2015
25. Schaafsma T, Wakefield J, Hanisch R, et al: Africa's oesophageal cancer corridor: Geographic variations in incidence correlate with certain micronutrient deficiencies. *PLoS One* 10:e0140107, 2015 [Erratum: *PLoS One* 10:e0142648, 2015]
26. Montesano R, Hollstein M, Hainaut P: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review. *Int J Cancer* 69:225-235, 1996
27. Hollstein MC, Peri L, Mandard AM, et al: Genetic analysis of human esophageal tumors from two high incidence geographic areas: Frequent p53 base substitutions and absence of ras mutations. *Cancer Res* 51:4102-4106, 1991
28. Abedi-Ardekani B, Kamangar F, Sotoudeh M, et al: Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. *PLoS One* 6:e29488, 2011
29. Tanière P, Martel-Planche G, Puttawibul P, et al: TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand. *Int J Cancer* 88:223-227, 2000

30. Alexandrov LB, Stratton MR: Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. *Curr Opin Genet Dev* 24:52-60, 2014
31. Liu W, Snell JM, Jeck WR, et al: Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. *JCI Insight* 1:e88755, 2016
32. Patel K, Mining S, Wakhisi J, et al: TP53 mutations, human papilloma virus DNA and inflammation markers in esophageal squamous cell carcinoma from the Rift Valley, a high-incidence area in Kenya. *BMC Res Notes* 4:469, 2011
33. Schäfer G, Kabanda S, van Rooyen B, et al: The role of inflammation in HPV infection of the oesophagus. *BMC Cancer* 13:185, 2013
34. White RE, Mungatana C, Mutuma G, et al: Absence of human papillomavirus in esophageal carcinomas from southwestern Kenya. *Dis Esophagus* 18:28-30, 2005
35. Mlombe Y, Dzamalala C, Chisi J, et al: Oesophageal cancer and Kaposi's sarcoma in Malawi: A comparative analysis. *Malawi Med J* 21:66-68, 2009
36. Sitas F, Pacella-Norman R, Carrara H, et al: The spectrum of HIV-1 related cancers in South Africa. *Int J Cancer* 88:489-492, 2000
37. White RE, Parker RK, Fitzwater JW, et al: Stents as sole therapy for oesophageal cancer: A prospective analysis of outcomes after placement. *Lancet Oncol* 10:240-246, 2009
38. Wei WQ, Chen ZF, He YT, et al: Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China. *J Clin Oncol* 33:1951-1957, 2015
39. World Health Organization: Cancer prevention and control in the context of an integrated approach. <http://apps.who.int/medicinedocs/en/d/Js23233en/>

